Trial Outcomes & Findings for Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers (NCT NCT04602611)

NCT ID: NCT04602611

Last Updated: 2025-01-30

Results Overview

The annualized count of acute care visits, where acute care visits included all unplanned inpatient admissions, emergency room encounters, and/or urgent care visits, was calculated for each subject as the total number of acute care visits normalized to an annual basis.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

228 participants

Primary outcome timeframe

From the date of randomization until subject discontinued the intervention, assessed up to 34 months

Results posted on

2025-01-30

Participant Flow

Participant milestones

Participant milestones
Measure
Standard of Care
Standard of Care
Oncology Nurse Navigation
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Overall Study
STARTED
115
113
Overall Study
COMPLETED
115
113
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard of Care
n=115 Participants
Standard of Care
Oncology Nurse Navigation
n=113 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Total
n=228 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
52 Participants
n=99 Participants
51 Participants
n=107 Participants
103 Participants
n=206 Participants
Age, Categorical
>=65 years
63 Participants
n=99 Participants
61 Participants
n=107 Participants
124 Participants
n=206 Participants
Age, Continuous
66 years
n=99 Participants
65 years
n=107 Participants
66 years
n=206 Participants
Sex: Female, Male
Female
34 Participants
n=99 Participants
52 Participants
n=107 Participants
86 Participants
n=206 Participants
Sex: Female, Male
Male
81 Participants
n=99 Participants
61 Participants
n=107 Participants
142 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants
n=99 Participants
2 Participants
n=107 Participants
10 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
106 Participants
n=99 Participants
111 Participants
n=107 Participants
217 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
26 Participants
n=99 Participants
30 Participants
n=107 Participants
56 Participants
n=206 Participants
Race (NIH/OMB)
White
85 Participants
n=99 Participants
80 Participants
n=107 Participants
165 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
115 participants
n=99 Participants
113 participants
n=107 Participants
228 participants
n=206 Participants
Diagnosis
Colorectal cancer (progression on or intolerant to fluorouracil, oxaliplatin and irinotecan therapy)
6 Participants
n=99 Participants
4 Participants
n=107 Participants
10 Participants
n=206 Participants
Diagnosis
Locally advanced unresectable pancreatic cancer
16 Participants
n=99 Participants
16 Participants
n=107 Participants
32 Participants
n=206 Participants
Diagnosis
Metastatic or unresectable biliary cancer
16 Participants
n=99 Participants
16 Participants
n=107 Participants
32 Participants
n=206 Participants
Diagnosis
Metastatic or unresectable gastroesophageal cancer
21 Participants
n=99 Participants
20 Participants
n=107 Participants
41 Participants
n=206 Participants
Diagnosis
Metastatic or unresectable hepatocellular carcinoma
15 Participants
n=99 Participants
16 Participants
n=107 Participants
31 Participants
n=206 Participants
Diagnosis
Metastatic pancreatic
41 Participants
n=99 Participants
41 Participants
n=107 Participants
82 Participants
n=206 Participants

PRIMARY outcome

Timeframe: From the date of randomization until subject discontinued the intervention, assessed up to 34 months

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date and (b) died within six months of enrollment or otherwise were on study for at least 6 months.

The annualized count of acute care visits, where acute care visits included all unplanned inpatient admissions, emergency room encounters, and/or urgent care visits, was calculated for each subject as the total number of acute care visits normalized to an annual basis.

Outcome measures

Outcome measures
Measure
Standard of Care
n=87 Participants
Standard of Care
Oncology Nurse Navigation
n=95 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Annualized Count of Acute Care Visits
3 unplanned acute care visits in one year
Interval 0.0 to 9.6
3.8 unplanned acute care visits in one year
Interval 1.3 to 7.7

PRIMARY outcome

Timeframe: From the date of randomization to death or 6 months

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date and (b) died within six months of enrollment or otherwise were on study for at least 6 months.

The proportion of participants surviving at 6 months was calculated for each treatment arm. Six-month overall survival was determined for each subject as a binary variable indicating whether or not the subject was alive at 6 months after study enrollment. Failure occurred if the subject died from any cause within 6 months of study enrollment. The proportions were compared between the arms.

Outcome measures

Outcome measures
Measure
Standard of Care
n=87 Participants
Standard of Care
Oncology Nurse Navigation
n=95 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Proportion of Participants Surviving at 6 Months
52 Participants
58 Participants

SECONDARY outcome

Timeframe: From the date of randomization up until 12 months

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date and (b) died within six months of enrollment or otherwise were on study for at least 6 months.

The proportion of participants surviving at 12 months was calculated for each treatment arm. Six-month overall survival was determined for each subject as a binary variable indicating whether or not the subject was alive at 12 months after study enrollment. Failure occurred if the subject died from any cause within 12 months of study enrollment. The proportions were compared between the arms.

Outcome measures

Outcome measures
Measure
Standard of Care
n=87 Participants
Standard of Care
Oncology Nurse Navigation
n=95 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Proportion of Participants Surviving at 12 Months
23 Participants
28 Participants

SECONDARY outcome

Timeframe: From the date of randomization until subject discontinued the intervention, assessed up to 34 months

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date and (b) died within six months of enrollment or otherwise were on study for at least 6 months.

Hospital length of stay was calculated for each subject as the total number of unplanned inpatient days while on intervention.

Outcome measures

Outcome measures
Measure
Standard of Care
n=87 Participants
Standard of Care
Oncology Nurse Navigation
n=95 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Hospital Length of Stay
1 Days
Interval 0.0 to 10.0
4 Days
Interval 0.0 to 92.0

SECONDARY outcome

Timeframe: From the date of hospice referral to death or last follow-up, assessed over 7 months.

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date, (b) died within six months of enrollment or otherwise were on study for at least 6 months, and (c) were referred to hospice (82/228 participants).

Time from hospice referral to death was a time-to-event endpoint defined as the time from hospice referral to the date of death from any cause. Subjects who were alive or lost to follow-up at the time of the analysis were censored at the last known date they were alive. This endpoint was only calculated for subjects referred to hospice.

Outcome measures

Outcome measures
Measure
Standard of Care
n=39 Participants
Standard of Care
Oncology Nurse Navigation
n=43 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Time From Hospice Referral to Death for Participants Referred to Hospice
0.427 months
Interval 0.263 to 0.755
0.526 months
Interval 0.296 to 1.084

SECONDARY outcome

Timeframe: From the date of randomization until subject discontinued the intervention, assessed up to 34 months

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date, (b) died within six months of enrollment or otherwise were on study for at least 6 months, and (c) had at least one in-patient admission (115/228 participants).

The number of readmissions within 30 days of in-patient admission discharges was calculated for each participant. This outcome was derived for each subject with at least one in-patient admission.

Outcome measures

Outcome measures
Measure
Standard of Care
n=51 Participants
Standard of Care
Oncology Nurse Navigation
n=64 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Total Number of 30-day Readmissions
0 number of 30-day readmissions
Interval 0.0 to 1.0
0 number of 30-day readmissions
Interval 0.0 to 1.0

SECONDARY outcome

Timeframe: From the date of randomization until subject discontinued the intervention, assessed up to 34 months

Population: Enrolled participants who both (a) receive at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date and (b) die within six months of enrollment or otherwise are on study for at least 6 months.

Referral to Supportive Care Services was derived for each participant as a binary variable indicating if there was at least one documented referral to Palliative Care, Nutrition Services, and/or Social Work Services.

Outcome measures

Outcome measures
Measure
Standard of Care
n=87 Participants
Standard of Care
Oncology Nurse Navigation
n=95 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Proportion of Participants Referred to Supportive Care Services
22 Participants
50 Participants

SECONDARY outcome

Timeframe: From the date of randomization until subject discontinued the intervention, assessed up to 34 months

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date and (b) died within six months of enrollment or otherwise were on study for at least 6 months.

This proportion was calculated for each participant as the percentage of missed visits of all scheduled within Atrium Health, regardless of visit type.

Outcome measures

Outcome measures
Measure
Standard of Care
n=87 Participants
Standard of Care
Oncology Nurse Navigation
n=95 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Proportions of Missed Visits of All Scheduled Visits From 0% to 100%.
3.1 percentage of missed scheduled visits
Interval 0.0 to 47.6
2.2 percentage of missed scheduled visits
Interval 0.0 to 60.0

SECONDARY outcome

Timeframe: From the date of randomization up until 14 weeks

Population: Enrolled participants who both (a) received at least one dose of standard of care systemic anti-cancer therapy on or after the enrollment date, (b) died within six months of enrollment or otherwise were on study for at least 6 months, and (c) completed the subject satisfaction survey 10-14 weeks after randomization (86/228 participants).

Subject satisfaction was assessed by a modified European Organization for Research and Treatment of Cancer Patient Satisfaction with cancer care questionnaire #33 (EORTC PATSAT C33) 10-14 weeks after randomization. Subjects completed the questionnaire assessing thirty-four elements of their experience with regards to hospital environment, hospital personnel, and treatment. Each question was assessed on a Likert-type scale ranging Poor to Excellent (mapped numerically to 1-5), where the higher scores indicated a better experience. The average score was calculated for each subject as the sum of the non-missing standardized scores divided by the number of measures contributing to the sum. The average score could range from 1 (the minimum) to 5 (the maximum).

Outcome measures

Outcome measures
Measure
Standard of Care
n=35 Participants
Standard of Care
Oncology Nurse Navigation
n=51 Participants
Standard of Care + Oncology Nurse Navigation Oncology Nurse Navigation: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Average Score of Subject Satisfaction as Assessed by an Adaptation of the EORTC PATSAT C33
4.4 score on a scale (out of 5)
Standard Deviation 0.6
4.6 score on a scale (out of 5)
Standard Deviation 0.5

Adverse Events

Standard of Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 72 deaths

Oncology Nurse Navigation

Serious events: 0 serious events
Other events: 0 other events
Deaths: 77 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Danielle M Boselli

Wake Forest

Phone: 2017903385

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place